- Home
- GGB vs MDGL Comparison
GGB vs MDGL Comparison
Compare GGB & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- MDGL
- Stock Information
- Founded
- GGB 1901
- MDGL 2011
- Country
- GGB Brazil
- MDGL United States
- Employees
- GGB N/A
- MDGL N/A
- Industry
- GGB Steel/Iron Ore
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- GGB Industrials
- MDGL Health Care
- Exchange
- GGB Nasdaq
- MDGL Nasdaq
- Market Cap
- GGB 5.7B
- MDGL 6.1B
- IPO Year
- GGB 1999
- MDGL N/A
- Fundamental
- Price
- GGB $3.14
- MDGL $417.43
- Analyst Decision
- GGB Strong Buy
- MDGL Strong Buy
- Analyst Count
- GGB 1
- MDGL 10
- Target Price
- GGB $3.80
- MDGL $474.67
- AVG Volume (30 Days)
- GGB 9.8M
- MDGL 329.8K
- Earning Date
- GGB 11-04-2025
- MDGL 10-30-2025
- Dividend Yield
- GGB 3.17%
- MDGL N/A
- EPS Growth
- GGB N/A
- MDGL N/A
- EPS
- GGB 0.29
- MDGL N/A
- Revenue
- GGB $12,681,996,398.00
- MDGL $515,547,000.00
- Revenue This Year
- GGB $6.81
- MDGL $394.12
- Revenue Next Year
- GGB $5.37
- MDGL $57.74
- P/E Ratio
- GGB $10.28
- MDGL N/A
- Revenue Growth
- GGB 6.96
- MDGL 3421.98
- 52 Week Low
- GGB $2.27
- MDGL $200.63
- 52 Week High
- GGB $3.62
- MDGL $457.16
- Technical
- Relative Strength Index (RSI)
- GGB 56.88
- MDGL 54.19
- Support Level
- GGB $3.03
- MDGL $418.36
- Resistance Level
- GGB $3.23
- MDGL $440.90
- Average True Range (ATR)
- GGB 0.08
- MDGL 13.63
- MACD
- GGB 0.00
- MDGL -5.66
- Stochastic Oscillator
- GGB 62.00
- MDGL 4.56
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutors, mechanical construction bars, and reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives the majority of its revenue from the Brazil Operations segment.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.